Use of big data for drug development and for public and personal health and care
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The use of data analytics across the entire healthcare value chain, from drug discovery and development through epidemiology to informed clinical decision for patients or policy making for public health, has seen an explosion in the recent years. The increase in quantity and variety of data available together with the improvement of storing capabilities and analytical tools offer numerous possibilities to all stakeholders (manufacturers, regulators, payers, healthcare providers, decision makers, researchers) but most importantly, it has the potential to improve general health outcomes if we learn how to exploit it in the right way. This article looks at the different sources of data and the importance of unstructured data. It goes on to summarize current and potential future uses in drug discovery, development, and monitoring as well as in public and personal healthcare; including examples of good practice and recent developments. Finally, we discuss the main practical and ethical challenges to unravel the full potential of big data in healthcare and conclude that all stakeholders need to work together towards the common goal of making sense of the available data for the common good.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Big data analytics in healthcare: promise and potential
Raghupathi, W., & Raghupathi, V. (2014) · Health Information Science and Systems · doi:10.1186/2047-2501-2-3 · Cited by 3,034 · cited 1×
“…in different fronts, from predictive modeling that lowers attrition to the improvement of clinical trial designs (e.g., endpoints, inclusion/exclusion criteria, etc.) that reduce trial failure and trial costs (reduced number of amendments and shorter completion times) (Raghupathi & Raghupathi 2014).”
BackgroundA rapid method for determining sequences in DNA by primed synthesis with DNA polymerase
Sanger, F., & Coulson, A. R. (1975) · Journal of Molecular Biology · doi:10.1016/0022-2836(75)90213-2 · Cited by 2,709 · cited 1×
“Since Sanger and Coulson published their first sequencing procedure 30 years ago (Sanger & Coulson, 1975), we have developed high throughput sequencing machines that are able to map human genome sequences in less than a week and more than 22,000 times cheaper than in 2001 (see Fig.”
Method(2014) · doi:10.1093/acprof:oso/9780199972036.001.0001 · Cited by 304
An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe
Horgan, D., Jansen, M., Leyens, L., Lal, J. A., Sudbrak, R., Hackenitz, E., Bußhoff, U., Ballensiefen, W., & Brand, A. (2014) · Public Health Genomics · doi:10.1159/000368034 · Cited by 91 · cited 1×
“We have not seeing dramatic applications of this concept in drug development yet (Horgan et al., 2014), with the usual time to develop pharmaceuticals being close to 10 years we should analyse after 2020 whether the expectative for big data in this area has materialised.”
BackgroundSelf-citationControlling Ebola through mHealth strategies
O'Donovan, J., & Bersin, A. (2015) · The Lancet Global Health · doi:10.1016/s2214-109x(14)70357-2 · Cited by 40 · cited 2×
“Visual analytics (Ola & Sedig, 2014) and predictive modelling (Davies et al., 2014) is an active area of research that could become an important building block to shape health policies and for public health professionals to engage in an agile manner and to predict and react to disease outbreaks…”
Background
Cited by
The emerging role of cognitive computing in healthcare: a systematic literature review
Behera, R. K., Bala, P. K., & Dhir, A. (2019) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2019.04.024 · Cited by 193
Dórea, F. C., & Revie, C. W. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.633977 · Cited by 27
Ethical Issues Raised by Artificial Intelligence and Big Data in Population Health: A Scoping Review
Couture, V., Roy, M.-C., Dez, E., Tremblay, F., & Bélisle-Pipon, J.-C. (2025) · Frontiers in Sociology · doi:10.3389/fsoc.2025.1536389 · Cited by 3
Metadata
- Authors
- Leyens, L., Reumann, M., Malats, N., & Brand, A.
- Venue
- Genetic Epidemiology
- Publisher
- Wiley
- Published
- 2016-11-21
- Volume
- 41
- Issue
- 1
- Pages
- 51-60
- ISSN
- 0741-0395 (ISSN-L)
- 1098-2272
- OpenAlex
- W2554634557
- Cited by
- 47
- References
- 5
- FWCI
- 15.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of big data for drug development and for public and personal health and care. https://app.cochat.ai/papers/10.1002/gepi.22012
- The paper
- Leyens, L., Reumann, M., Malats, N., & Brand, A. (2017). Use of big data for drug development and for public and personal health and care. Genetic Epidemiology. https://doi.org/10.1002/gepi.22012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.